Back to Directory
Orforglipron
Metabolic & Weight ManagementOral non-peptide GLP-1 receptor agonist, first potential oral daily GLP-1 pill.
Key Benefits
- ✓Oral daily pill (no injection)
- ✓Significant weight loss
- ✓Improves glucose control
- ✓Convenient oral administration
- ✓Non-peptide GLP-1 agonist
Dosing Information
Dosage Range
Under investigation
Frequency
Once daily oral
Typical Duration
Phase 3 trials
Detailed Protocol
Under development as oral once-daily tablet. Taken in the morning on empty stomach in trials. Phase 3 trials ongoing.
About Orforglipron
Orforglipron (LY3502970) is a non-peptide small molecule GLP-1 receptor agonist that can be taken orally once daily. Unlike peptide GLP-1 agonists, it does not require injection. Being developed by Eli Lilly for obesity and type 2 diabetes.
Research Notes
Phase 2 ACHIEVE-1 trial showed 14.7% weight loss at 45mg dose. First oral daily GLP-1 agonist in late-stage development. Could revolutionize GLP-1 therapy if approved.
Potential Side Effects
- •Nausea and vomiting
- •Diarrhea
- •Abdominal pain
- •Constipation
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.